Cinaciguat
(Synonyms: BAY 58-2667) 目录号 : GC10962
An activator of sGC
Cas No.:329773-35-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | After confirmation of DM, rats are randomised into four groups: vehicle-treated control, cinaciguat-treated control, vehicle-treated diabetic and cinaciguat-treated diabetic groups. Animals are treated for 8 weeks with 0.5% methylcellulose vehicle or with the sGC activator cinaciguat in suspension p.o. (10 mg/kg/day), starting immeadiately after DM confirmation. Water bottles are filled every morning with the same amount of fresh tap water and daily water intake is measured. Animal cages are handled with care and are not moved after water bottle replacement to prevent spilling of water from the bottles. Body weight of the animals are recorded every 2 days and the dose of cinaciguat is adjusted accordingly. |
References: [1]. Mátyás C, et al. The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus. Cardiovasc Diabetol. 2015 Oct 31;14:145. | |
Cinaciguat, also known as BAY-58-2667, is a NO-independent activator for sGC with EC50 of ∼10 nM for heme-free/oxidized sGC. [1]
Heme-related dysfunction can lead to cardiovascular diseases with the oxidation of the heme of soluble guanylate cyclase (sGC) critically implicated in some of these cardiovascular diseases. sGC, the main nitric oxide receptor, stimulates second messenger cGMP production, however reactive oxygen species are known to scavenge NO and oxidize/inactivate the heme leading to sGC degradation. Cinaciguat binding causes a rotation of the α- helix away from the heme pocket, as this helix is normally held in place via the inhibitory His105–heme covalent bond. [2]
Cinaciguat activates sGC with EC 50 and Kd values in the low nanomolar range. This renders the compound the most potent NO-independent sGC activator reported to date. Furthermore, cinaciguat produces an additive, non-synergistic effect when combined with NO donors. Cinaciguat could also relaxe blood vessels with a high potency which is several orders of magnitude greater than the NO-donors sodium nitroprusside (SNP) and 3-morpho-linosydnonimin. In addition, the compound reduces coronary perfusion pressure in the rat Langendorff heart preparation and remains active in tissues made tolerant to glyceryl trinitrate. [1]
Cinaciguat could protect cardiomyocytes against ischemia/reperfusion injuries. Cinaciguat caused 63 and 41% reduction of infarct size when given before I/R and at reperfusion in rabbits, respectively. In addition, cinaciguat pretreatment caused a more robust 80% reductionin infarct size vs. 63% reduction when given at reperfusion and preserved cardiac function following I/R in mice, through cGMP-PKG-dependent generation of H2S in the heart and cardiomyocytes.[3]
References:
[1] Evgenov, Oleg V., et al. "NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential." Nature reviews Drug discovery 5.9 (2006): 755-768.
[2] Martin, Faye, et al. "Structure of cinaciguat (BAY 58–2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase." Journal of Biological Chemistry 285.29 (2010): 22651-22657.
[3] Salloum, Fadi N., et al. "Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide."American Journal of Physiology-Heart and Circulatory Physiology 302.6 (2012): H1347-H1354.
| Cas No. | 329773-35-5 | SDF | |
| 别名 | BAY 58-2667 | ||
| 化学名 | 4-[[4-carboxybutyl-[2-[2-[[4-(2-phenylethyl)phenyl]methoxy]phenyl]ethyl]amino]methyl]benzoic acid | ||
| Canonical SMILES | C1=CC=C(C=C1)CCC2=CC=C(C=C2)COC3=CC=CC=C3CCN(CCCCC(=O)O)CC4=CC=C(C=C4)C(=O)O | ||
| 分子式 | C36H39NO5 | 分子量 | 565.7 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7677 mL | 8.8386 mL | 17.6772 mL |
| 5 mM | 0.3535 mL | 1.7677 mL | 3.5354 mL |
| 10 mM | 0.1768 mL | 0.8839 mL | 1.7677 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。